Despite political and economic pressures, researchers remain focused on collaboration, automation, and investment

As uncertainty looms over the life sciences industry, scientists are preparing for turbulence without halting progress. According to LINUS’s latest State of Science report, 71% of researchers across pharma, biotech, and academia anticipate a recession in 2025—yet 60% still plan to maintain or increase their purchasing of lab products.

The global survey of 450 scientists, conducted by LINUS, reveals a community under pressure but not paralyzed. While fears of budget cuts run high—particularly in academia—most concerns are driven by sentiment rather than reality. Just 21% of respondents have seen actual reductions to their budgets.

“The industry is adjusting, not retreating,” said Hamid Ghanadan, CEO of LINUS. “Our data show that scientists are not paralyzed—they’re seeking new collaborations, prioritizing automation, and making strategic technology investments.”

Among industry respondents, biopharma appears notably resilient: 62% expressed confidence in their ability to meet 2025 productivity goals. In contrast, only 41% of academic scientists shared the same outlook.

Political pressure, public trust, and a shifting definition of productivity

The politicization of scientific topics has emerged as the leading barrier to progress, named by 39% of scientists—up 15 percentage points since January. This concern is especially acute in the U.S., where nearly half of academic researchers cited politicization among their top three challenges. Half of U.S.-based scientists also expect public trust in science to continue eroding this year.

While 57% of respondents believe scientific leaders should do more public communication, only 11% of U.S. labs plan to increase outreach, revealing what the report calls a “responsibility gap.”

Scientific journals and peer networks remain the most trusted sources of information, despite ongoing concerns about reproducibility.

AI becomes a strategic focus—but sequencing wins in spending

Artificial intelligence now dominates strategic thinking, with 36% of scientists placing AI adoption among their top three priorities. Tools for machine learning and generative AI are expected to have significant impact in the year ahead. However, when it comes to capital purchases, sequencing instruments are more likely to make it into lab budgets.

Bioinformatics and predictive modeling were also identified as key drivers of impact, cited by 60% of respondents. Notably, 42% of scientists said they now prioritize collaboration over internal expansion.

Collaboration and automation rise as confidence dips

A major shift toward collaboration is underway, with 53% of scientists actively pursuing partnerships to unlock new funding streams. At the same time, 40% are investing in workflow automation to drive efficiency and productivity.

Despite this activity, overall confidence in hitting 2025 goals has declined since January—from 62% to 50%. This dip is most visible in academia, while biopharma remains more optimistic. Notably, definitions of success vary: academic researchers continue to measure productivity in terms of publications and funding, while those in industry look toward commercial milestones and project delivery.

Recommendations for life science providers

In a year marked by volatility and change, life science companies have an opportunity to support scientists not only as suppliers, but as advocates. LINUS suggests that vendors focus on three key actions:

• Understand sector-specific pressures: Tailor messaging and support to the differing needs of academia and industry.

• Show thought leadership: Scientists want partners who contribute to the wider discourse—not just transactional relationships.

• Enable productivity: From automation tools to collaborative platforms, products and services must align with researchers’ evolving definitions of success.

“To thrive in this era, companies must deliver with specificity, partnership, and purpose,” said Ghanadan.